Skip to main content

Table 5 Statistical difference ( P values) between the performance of PET/CT and cePET/CT for each analyzed tumor type, site of disease, and clinical question

From: Contrast-enhanced [18 F] fluorodeoxyglucose-positron emission tomography/computed tomography in clinical oncology: tumor-, site-, and question-based comparison with standard positron emission tomography/computed tomography

  P value
Tumor type  
Lung cancer 0.12
Head and neck cancer 0.02
Gastrointestinal cancera 0.0002
Breast cancer 0.09
Lymphoma 0.24
Melanoma 0.16
Multiple melanoma 0.08
Otherb 0.33
Site of disease  
Neck 0.096
Thorax 0.36
Abdomen 0.009
Skeleton-bone marrow 0.33
Lymph nodes 0.44
Clinical question  
Diagnosis 0.39
Staging 0.09
Restagingc 0.003
Response to chemotherapy 0.13
Response to radiotherapy 0.1
Post-surgery evaluation 0.54
Surveillance 0.51
  1. aIncluding esophageal, gastric, and colorectal cancer.
  2. bGynecologic malignancy n = 8 , testicular cancer n = 2, sarcoma n = 3, low-differentiated neuroendocrine carcinoma n = 4, thymoma n = 1.
  3. cSuspected relapse or patients with potentially resectable metastatic disease.
  4. PET, positron emission tomography; CT, computed tomography; cePET/CT, contrast-enhanced PET/ CT.